CHU Bordeaux
Bordeaux, France
Location status: Recruiting
NCT Number: NCT05675969
A large number of studies on MVs from syncytiotrophoblasts support the hypothesis of their involvement in pre-eclampsia, via their multiple effects, among others as pro-coagulant, immuno-stimulatory and anti-angiogenic factors.
The main objective is to compare the total concentration of the main populations of MVs in the maternal blood of a population of pre-eclamptic patients to those of a population of non-pre-eclamptic patients.
Interested in participating?
Request Info18 year and older
Female
Interventional
Not applicable
Bordeaux, France
Location status: Recruiting
Activated or apoptotic cells release membrane fragments called microvesicles, microparticles, extracellular vesicles or exosomes into the extracellular environment. The term microvesicle (MV) used in this project encompasses all membrane fragments secreted by cells, regardless of their cellular origin, their size or the membrane compartment from which they originate.
The presence on the surface of MVs and in their reservoir of elements from their parent cell, such as surface receptors, mRNAs or microRNAs, led to the hypothesis that MVs could serve as biomarkers, revealing the existence of tissues in distress in the body.
Under physiological conditions, blood plasma contains mainly MVs from red blood cells and platelets, the main circulating cell populations. During pregnancy, the presence of membrane fragments of placental origin in the maternal circulation has long been established. A large number of studies on syncytiotrophoblast-derived MVs support the hypothesis of their involvement in pre-eclampsia, via their multiple effects, among others as pro-coagulant, immuno-stimulatory, anti-angiogenic factors.
The "Membrane Repair and Extracellular Vesicles" team within the CBMN laboratory of the University of Bordeaux has developed original approaches to characterize and quantify MVs, mainly by cryo-electron microscopy, immunogold labeling and flow cytometry. In addition, recent developments from this team allow the analysis of MVs in whole blood, which is a major advantage.
The main objective is to compare the total concentration of the main populations of MVs in the maternal blood of a population of pre-eclamptic patients to those of a population of non-pre-eclamptic patients.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Collection of 2 additional tubes of 4.5mL of citrate blood
Time frame: baseline
Total concentration (number of MVs / µL) of the main MV populations, (MVs of erythrocyte, platelet or placental origin, determined by flow cytometry)
Time frame: baseline
Concentration (number of MVs / µL) of MVs of erythrocyte origin by flow cytometry
Time frame: baseline
Concentration (number of MVs / µL) of MVs of platelet origin by flow cytometry
Time frame: baseline
Concentration (number of MVs / µL) of MVs of placental origin determined by flow cytometry
Time frame: baseline
Rate of MVs
Time frame: baseline
Gravidic hypertension (≥ 160/110 mmHg)
Contact information is provided by the study sponsor or research team.
Alain Brisson, PhD
CONTACT
Loic Sentilhes, MD, PhD
CONTACT
University Hospital, Bordeaux
Other
Study of Microvesicles in Pre-eclampsia
Acronym: MICROVES-PE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07470320
Cardiovascular Diseases, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Oxford, United Kingdom
View Trial DetailsNCT06108947
Female Urogenital Diseases and Pregnancy Complications, Hypertension, Pregnancy-Induced
Trondheim, Norway
View Trial DetailsNCT04356326
Abruptio Placentae, Aspirin
Bordeaux, France
View Trial DetailsNCT03626233
Female Urogenital Diseases and Pregnancy Complications, Hypertension, Pregnancy-Induced
Créteil, France
View Trial Details